Supply agreement between STA and TESARO signed

Small molecule pharmaceutical development and manufacturing capability and technology platform company, STA Pharmaceutical, has entered into a five-year supply agreement with oncology-focused biopharma company, TESARO.

Under the terms of the agreement, STA will provide supplies of certain starting and intermediate materials for ZEJULA, which is an orally active and potent poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer that was launched recently.

ZEJULA was approved for the treatment of epithelial ovarian, fallopian tube or primary peritoneal cancer by the US Food and Drug Administration (FDA) earlier this year and is currently available to patients in the US.

This supply agreement follows the successful multiple-year development and clinical manufacturing arrangement with TESARO, involving assistance with the expedited new drug application submission and final approval by the FDA.

“We have been working with TESARO for a number of years, and we are honoured to be selected as a TESARO global supplies partner for this critical life-saving drug,” said Dr Minzhang Chen, CEO of STA Pharmaceutical. “STA is committed to helping our partners develop and commercialize innovative breakthrough drugs like ZEJULA via our state-of-the-art enabling platform. It has been an extremely successful partnership and we look forward to working alongside the TESARO team to expedite their development and commercial timelines.”